BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
US |
|
E
|
Etteplan Oyj
OMXH:ETTE
|
FI |
|
Tubos Reunidos SA
MAD:TRG
|
ES |
|
O
|
Old Dominion Freight Line Inc
XBER:ODF
|
US |
|
F
|
Federal Home Loan Mortgage Corp
OTC:FMCC
|
US |
|
W
|
WICE Logistics PCL
SET:WICE
|
TH |
|
Kohls Corp
NYSE:KSS
|
US |
|
C
|
Charles Schwab Corp
BMV:SCHW
|
US |
|
G
|
Gap Inc
LSE:0ITS
|
US |
|
Amphenol Corp
NYSE:APH
|
US |
|
Global Lithium Resources Ltd
ASX:GL1
|
AU |
|
Cantaloupe Inc
NASDAQ:CTLP
|
US |
|
Caixabank SA
MAD:CABK
|
ES |
|
L
|
Laser Photonics Corp
NASDAQ:LASE
|
US |
|
I
|
International Zeolite Corp
OTC:IZCFF
|
CA |
|
P
|
PA Resources Bhd
KLSE:PA
|
MY |
|
Atul Ltd
BSE:500027
|
IN |
|
Orezone Gold Corp
F:OEX
|
CA |
|
LHV Group AS
F:ASU0
|
EE |
|
DC Infotech and Communication Ltd
NSE:DCI
|
IN |
|
Owens & Minor Inc
NYSE:ACH
|
US |
|
R
|
RT Minerals Corp
OTC:RTMFF
|
CA |
|
Marvel Discovery Corp
XTSX:MARV
|
CA |
Wall St Price Targets
BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for BCRX is 21.73 USD with a low forecast of 13.13 USD and a high forecast of 33.6 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BCRX's stock price target?
Price Target
21.73
USD
According to Wall Street analysts, the average 1-year price target for BCRX is 21.73 USD with a low forecast of 13.13 USD and a high forecast of 33.6 USD.
What is the Revenue forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
0%
Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 3 years is 0%.
What is the Gross Profit forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-1%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 31%. The projected CAGR for the next 3 years is -1%.
What is the Operating Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-13%
The compound annual growth rate for Operating Income over the next 3 years is -13%.
What is the Pre-Tax Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-19%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -19%.
What is the Net Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
-25%
The compound annual growth rate for Net Income over the next 3 years is -25%.
